Animal models of COPD: What do they tell us?

Respirology

Volumn 22, Issue 1, 2017, Pages 21-32

  Jones, Bernadette ^a   Donovan, Chantal ^a   Liu, Gang ^a   Gomez, Henry M ^a   Chimankar, Vrushali ^a   Harrison, Celeste L ^a   Wiegman, Cornelis H ^b   Adcock, Ian M ^b   Knight, Darryl A ^a   Hirota, Jeremy A ^c   Hansbro, Philip M ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

animal models; chronic obstructive pulmonary disease; disease mechanisms; therapeutic targets; therapies

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; ABX IL8; BIOLOGICAL MARKER; CIGARETTE SMOKE; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MONOCLONAL ANTIBODY; THEOPHYLLINE; UNCLASSIFIED DRUG; ZD 0892;

AIR POLLUTION; AIRWAY REMODELING; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; BACTERIAL INFECTION; BRONCHODILATATION; CHLAMYDIA PNEUMONIAE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOKINE RELEASE; DISEASE EXACERBATION; DISEASE MODEL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESEARCH; DRUG TARGETING; FERRET; GUINEA PIG; INNATE IMMUNITY; LOW DRUG DOSE; LUNG EMPHYSEMA; LUNG FUNCTION; LUNG INSUFFICIENCY; MEDICAL RESEARCH; MOUSE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RAT; REVIEW; SEX DIFFERENCE; SYMPTOMATOLOGY; VIRUS INFECTION; ANIMAL; HUMAN; PATHOLOGY;

AIRWAY REMODELING; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84995489135     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12908     Document Type: Review

References (106)

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095–128.
2. Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, Nair H, Gasevic D, Sridhar D, Campbell H et al.; Global Health Epidemiology Reference Group. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J. Glob. Health 2015; 5: 020415.
3. Hsu AC, See HV, Hansbro PM, Wark PA. Innate immunity to influenza in chronic airways diseases. Respirology 2012; 17: 1166–75.
4. Vlahos R, Bozinovski S, Gualano R, Ernst M, Anderson G. Modelling COPD in mice. Pulm. Pharmacol. Ther. 2006; 19: 12–7.
5. Hecht SS. Tobacco smoke carcinogens and lung cancer. J. Natl. Cancer Inst. 1999; 91: 1194–210.
6. Selman M, Montano M, Ramos C, Vanda B, Becerril C, Delgado J, Sansores R, Barrios R, Pardo A. Tobacco smoke-induced lung emphysema in guinea pigs is associated with increased interstitial collagenase. Am. J. Physiol. 1996; 271: L734–43.
7. Wright JL, Farmer SG, Churg A. Synthetic serine elastase inhibitor reduces cigarette smoke-induced emphysema in guinea pigs. Am. J. Respir. Crit. Care Med. 2002; 166: 954–60.
8. Golovatch P, Mercer BA, Lemaitre V, Wallace A, Foronjy RF, D'Armiento J. Role for cathepsin K in emphysema in smoke-exposed guinea pigs. Exp. Lung Res. 2009; 35: 631–45.
9. Ofulue AF, Ko M. Effects of depletion of neutrophils or macrophages on development of cigarette smoke-induced emphysema. Am. J. Physiol. 1999; 277: L97–105.
10. Roh GS, Yi CO, Cho YJ, Jeon BT, Nizamudtinova IT, Kim HJ, Kim JH, Oh YM, Huh JW, Lee JH et al. Anti-inflammatory effects of celecoxib in rat lungs with smoke-induced emphysema. Am. J. Physiol. Lung Cell. Mol. Physiol. 2010; 299: L184–91.
11. Kratzer A, Salys J, Nold-Petry C, Cool C, Zamora M, Bowler R, Koczulla AR, Janciauskiene S, Edwards MG, Dinarello CA et al. Role of IL-18 in second-hand smoke-induced emphysema. Am. J. Respir. Cell Mol. Biol. 2013; 48: 725–32.
12. Birrell MA, Wong S, Hele DJ, McCluskie K, Hardaker E, Belvisi MG. Steroid-resistant inflammation in a rat model of chronic obstructive pulmonary disease is associated with a lack of nuclear factor-kappaB pathway activation. Am. J. Respir. Crit. Care Med. 2005; 172: 74–84.
13. Nie YC, Wu H, Li PB, Luo YL, Zhang CC, Shen JG, Su WW. Characteristic comparison of three rat models induced by cigarette smoke or combined with LPS: to establish a suitable model for study of airway mucus hypersecretion in chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2012; 25: 349–56.
14. Nakanishi Y, Kobayashi D, Asano Y, Sakurai T, Kashimura M, Okuyama S, Yoneda Y, Shapiro SD, Takayama K. Clarithromycin prevents smoke-induced emphysema in mice. Am. J. Respir. Crit. Care Med. 2009; 179: 271–8.
15. Churg A, Zhou S, Wang X, Wang R, Wright JL. The role of interleukin-1beta in murine cigarette smoke-induced emphysema and small airway remodeling. Am. J. Respir. Cell Mol. Biol. 2009; 40: 482–90.
16. Foronjy RF, Mercer BA, Maxfield MW, Powell CA, D'Armiento J, Okada Y. Structural emphysema does not correlate with lung compliance: lessons from the mouse smoking model. Exp. Lung Res. 2005; 31: 547–62.
17. D'Hulst AI, Vermaelen KY, Brusselle GG, Joos GF, Pauwels RA. Time course of cigarette smoke-induced pulmonary inflammation in mice. Eur. Respir. J. 2005; 26: 204–13.
18. March TH, Wilder JA, Esparza DC, Cossey PY, Blair LF, Herrera LK, McDonald JD, Campen MJ, Mauderly JL, Seagrave J. Modulators of cigarette smoke-induced pulmonary emphysema in A/J mice. Toxicol. Sci. 2006; 92: 545–59.
19. Hodge-Bell KC, Lee KM, Renne RA, Gideon KM, Harbo SJ, McKinney WJ. Pulmonary inflammation in mice exposed to mainstream cigarette smoke. Inhal. Toxicol. 2007; 19: 361–76.
20. Braber S, Henricks PA, Nijkamp FP, Kraneveld AD, Folkerts G. Inflammatory changes in the airways of mice caused by cigarette smoke exposure are only partially reversed after smoking cessation. Respir. Res. 2010; 11: 99.
21. Rinaldi M, Maes K, De Vleeschauwer S, Thomas D, Verbeken EK, Decramer M, Janssens W, Gayan-Ramirez GN. Long-term nose-only cigarette smoke exposure induces emphysema and mild skeletal muscle dysfunction in mice. Dis. Model. Mech. 2012; 5: 333–41.
22. Gualano RC, Hansen MJ, Vlahos R, Jones JE, Park-Jones RA, Deliyannis G, Turner SJ, Duca KA, Anderson GP. Cigarette smoke worsens lung inflammation and impairs resolution of influenza infection in mice. Respir. Res. 2008; 9: 53.
23. Donovan C, Seow HJ, Royce SG, Bourke JE, Vlahos R. Alteration of airway reactivity and reduction of ryanodine receptor expression by cigarette smoke in mice. Am. J. Respir. Cell Mol. Biol. 2015; 53: 471–8.
24. Beckett EL, Stevens RL, Jarnicki AG, Kim RY, Hanish I, Hansbro NG, Deane A, Keely S, Horvat JC, Yang M et al. A new short-term mouse model of chronic obstructive pulmonary disease identifies a role for mast cell tryptase in pathogenesis. J. Allergy Clin. Immunol. 2013; 131: 752–62.
25. Chen-Yu Hsu A, Starkey MR, Hanish I, Parsons K, Haw TJ, Howland LJ, Barr I, Mahony JB, Foster PS, Knight DA et al. Targeting PI3K-p110alpha suppresses influenza virus infection in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2015; 191: 1012–23.
26. Franklin BS, Bossaller L, De Nardo D, Ratter JM, Stutz A, Engels G, Brenker C, Nordhoff M, Mirandola SR, Al-Amoudi A et al. The adaptor ASC has extracellular and ‘prionoid’ activities that propagate inflammation. Nat. Immunol. 2014; 15: 727–37.
27. Haw TJ, Starkey MR, Nair PM, Pavlidis S, Liu G, Nguyen DH, Hsu AC, Hanish I, Kim RY, Collison AM et al. A pathogenic role for tumor necrosis factor-related apoptosis-inducing ligand in chronic obstructive pulmonary disease. Mucosal Immunol. 2016; 9: 859–72.
28. Wright JL, Churg A. Cigarette smoke causes physiologic and morphologic changes of emphysema in the guinea pig. Am. Rev. Respir. Dis. 1990; 142: 1422–8.
29. Heck JD, Gaworski CL, Rajendran N, Morrissey RL. Toxicologic evaluation of humectants added to cigarette tobacco: 13-week smoke inhalation study of glycerin and propylene glycol in Fischer 344 rats. Inhal. Toxicol. 2002; 14: 1135–52.
30. Raju SV, Solomon GM, Dransfield MT, Rowe SM. Acquired cystic fibrosis transmembrane conductance regulator dysfunction in chronic bronchitis and other diseases of mucus clearance. Clin. Chest Med. 2016; 37: 147–58.
31. Liu C, Russell RM, Wang XD. Lycopene supplementation prevents smoke-induced changes in p53, p53 phosphorylation, cell proliferation, and apoptosis in the gastric mucosa of ferrets. J. Nutr. 2006; 136: 106–11.
32. Kim Y, Liu XS, Liu C, Smith DE, Russell RM, Wang XD. Induction of pulmonary neoplasia in the smoke-exposed ferret by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK): a model for human lung cancer. Cancer Lett. 2006; 234: 209–19.
33. Liu C, Bronson RT, Russell RM, Wang XD. beta-Cryptoxanthin supplementation prevents cigarette smoke-induced lung inflammation, oxidative damage, and squamous metaplasia in ferrets. Cancer Prev. Res. (Phila.) 2011; 4: 1255–66.
34. Zheng H, Liu Y, Huang T, Fang Z, Li G, He S. Development and characterization of a rat model of chronic obstructive pulmonary disease (COPD) induced by sidestream cigarette smoke. Toxicol. Lett. 2009; 189: 225–34.
35. Li Y, Li SY, Li JS, Deng L, Tian YG, Jiang SL, Wang Y, Wang YY. A rat model for stable chronic obstructive pulmonary disease induced by cigarette smoke inhalation and repetitive bacterial infection. Biol. Pharm. Bull. 2012; 35: 1752–60.
36. Stinn W, Teredesai A, Anskeit E, Rustemeier K, Schepers G, Schnell P, Haussmann HJ, Carchman RA, Coggins CR, Reininghaus W. Chronic nose-only inhalation study in rats, comparing room-aged sidestream cigarette smoke and diesel engine exhaust. Inhal. Toxicol. 2005; 17: 549–76.
37. Van Miert E, Dumont X, Bernard A. CC16 as a marker of lung epithelial hyperpermeability in an acute model of rats exposed to mainstream cigarette smoke. Toxicol. Lett. 2005; 159: 115–23.
38. Yates SL, Bencherif M, Fluhler EN, Lippiello PM. Upregulation of nicotinic acetylcholine receptors following chronic exposed of rats to mainstream cigarette smoked or a4b2 receptors to nicotine. Biochem. Pharmacol. 1995; 50: 2001–8.
39. Gaschler GJ, Bauer CM, Zavitz CC, Stampfli MR. Animal models of chronic obstructive pulmonary disease exacerbations. Contrib. Microbiol. 2007; 14: 126–41.
40. Tay HL, Kaiko GE, Plank M, Li J, Maltby S, Essilfie AT, Jarnicki A, Yang M, Mattes J, Hansbro PM et al. Antagonism of miR-328 increases the antimicrobial function of macrophages and neutrophils and rapid clearance of non-typeable Haemophilus influenzae (NTHi) from infected lung. PLoS Pathog. 2015; 11: e1004549.
41. Starkey MR, Jarnicki AG, Essilfie AT, Gellatly SL, Kim RY, Brown AC, Foster PS, Horvat JC, Hansbro PM. Murine models of infectious exacerbations of airway inflammation. Curr. Opin. Pharmacol. 2013; 13: 337–44.
42. Zheng T, Zhu Z, Wang Z, Homer RJ, Ma B, Riese RJ Jr, Chapman HA Jr, Shapiro SD, Elias JA. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J. Clin. Invest. 2000; 106: 1081–93.
43. Sobinoff AP, Sutherland JM, Beckett EL, Stanger SJ, Johnson R, Jarnicki AG, McCluskey A, St John JC, Hansbro PM, McLaughlin EA. Damaging legacy: maternal cigarette smoking has long-term consequences for male offspring fertility. Hum. Reprod. 2014; 29: 2719–35.
44. Wiegman CH, Michaeloudes C, Haji G, Narang P, Clarke CJ, Russell KE, Bao W, Pavlidis S, Barnes PJ, Kanerva J et al.; COPDMAP. Oxidative stress-induced mitochondrial dysfunction drives inflammation and airway smooth muscle remodeling in patients with chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2015; 136: 769–80.
45. Miyabara Y, Ichinose T, Takano H, Lim HB, Sagai M. Effects of diesel exhaust on allergic airway inflammation in mice. J. Allergy Clin. Immunol. 1998; 102: 805–12.
46. Hirota JA, Gold MJ, Hiebert PR, Parkinson LG, Wee T, Smith D, Hansbro PM, Carlsten C, VanEeden S, Sin DD et al. The nucleotide-binding domain, leucine-rich repeat protein 3 inflammasome/IL-1 receptor I axis mediates innate, but not adaptive, immune responses after exposure to particulate matter under 10 mum. Am. J. Respir. Cell Mol. Biol. 2015; 52: 96–105.
47. Hirota JA, Hirota SA, Warner SM, Stefanowicz D, Shaheen F, Beck PL, Macdonald JA, Hackett TL, Sin DD, Van Eeden S et al. The airway epithelium nucleotide-binding domain and leucine-rich repeat protein 3 inflammasome is activated by urban particulate matter. J. Allergy Clin. Immunol. 2012; 129: 1116–25.e6.
48. Li N, Wang M, Bramble LA, Schmitz DA, Schauer JJ, Sioutas C, Harkema JR, Nel AE. The adjuvant effect of ambient particulate matter is closely reflected by the particulate oxidant potential. Environ. Health Perspect. 2009; 117: 1116–23.
49. Triantaphyllopoulos K, Hussain F, Pinart M, Zhang M, Li F, Adcock I, Kirkham P, Zhu J, Chung KF. A model of chronic inflammation and pulmonary emphysema after multiple ozone exposures in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 2011; 300: L691–700.
50. Wiegman CH, Li F, Clarke CJ, Jazrawi E, Kirkham P, Barnes PJ, Adcock IM, Chung KF. A comprehensive analysis of oxidative stress in the ozone-induced lung inflammation mouse model. Clin. Sci. 2014; 126: 425–40.
51. Russell KE, Chung KF, Clarke CJ, Durham AL, Mallia P, Footitt J, Johnston SL, Barnes PJ, Hall SR, Simpson KD et al. The MIF antagonist ISO-1 attenuates corticosteroid-insensitive inflammation and airways hyperresponsiveness in an ozone-induced model of COPD. PLoS One 2016; 11: e0146102.
52. Spond J, Billah MM, Chapman RW, Egan RW, Hey JA, House A, Kreutner W, Minnicozzi M. The role of neutrophils in LPS-induced changes in pulmonary function in conscious rats. Pulm. Pharmacol. Ther. 2004; 17: 133–40.
53. Stolk J, Rudolphus A, Davies P, Osinga D, Dijkman JH, Agarwal L, Keenan KP, Fletcher D, Kramps JA. Induction of emphysema and bronchial mucus cell hyperplasia by intratracheal instillation of lipopolysaccharide in the hamster. J. Pathol. 1992; 167: 349–56.
54. Kobayashi S, Fujinawa R, Ota F, Kobayashi S, Angata T, Ueno M, Maeno T, Kitazume S, Yoshida K, Ishii T et al. A single dose of lipopolysaccharide into mice with emphysema mimics human chronic obstructive pulmonary disease exacerbation as assessed by micro-computed tomography. Am. J. Respir. Cell Mol. Biol. 2013; 49: 971–7.
55. Drannik AG, Pouladi MA, Robbins CS, Goncharova SI, Kianpour S, Stampfli MR. Impact of cigarette smoke on clearance and inflammation after Pseudomonas aeruginosa infection. Am. J. Respir. Crit. Care Med. 2004; 170: 1164–71.
56. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 2007; 47: 89–116.
57. Goven D, Boutten A, Lecon-Malas V, Marchal-Somme J, Amara N, Crestani B, Fournier M, Leseche G, Soler P, Boczkowski J et al. Altered Nrf2/Keap1-Bach1 equilibrium in pulmonary emphysema. Thorax 2008; 63: 916–24.
58. Biswal S, Thimmulappa RK, Harvey CJ. Experimental therapeutics of Nrf2 as a target for prevention of bacterial exacerbations in COPD. Proc. Am. Thorac. Soc. 2012; 9: 47–51.
59. Donovan C, Seow Huei J, Bourke Jane E, Vlahos R. Influenza A virus infection and cigarette smoke impair bronchodilator responsiveness to β-adrenoceptor agonists in mouse lung. Clin. Sci. 2016; 130: 829–37.
60. Kimura G, Ueda K, Eto S, Watanabe Y, Masuko T, Kusama T, Barnes PJ, Ito K, Kizawa Y. Toll-like receptor 3 stimulation causes corticosteroid-refractory airway neutrophilia and hyperresponsiveness in mice. Chest 2013; 144: 99–105.
61. Kang MJ, Lee CG, Lee JY, Dela Cruz CS, Chen ZJ, Enelow R, Elias JA. Cigarette smoke selectively enhances viral PAMP- and virus-induced pulmonary innate immune and remodeling responses in mice. J. Clin. Invest. 2008; 118: 2771–84.
62. Botelho FM, Bauer CM, Finch D, Nikota JK, Zavitz CC, Kelly A, Lambert KN, Piper S, Foster ML, Goldring JJ et al. IL-1alpha/IL-1R1 expression in chronic obstructive pulmonary disease and mechanistic relevance to smoke-induced neutrophilia in mice. PLoS One 2011; 6: e28457.
63. Donovan C, Bourke JE, Vlahos R. Targeting the IL-33/IL-13 axis for respiratory viral infections. Trends Pharmacol. Sci. 2016; 37: 252–61.
64. Kearley J, Silver JS, Sanden C, Liu Z, Berlin AA, White N, Mori M, Pham TH, Ward CK, Criner GJ et al. Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection. Immunity 2015; 42: 566–79.
65. Byers DE, Alexander-Brett J, Patel AC, Agapov E, Dang-Vu G, Jin X, Wu K, You Y, Alevy Y, Girard JP et al. Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease. J. Clin. Invest. 2013; 123: 3967–82.
66. Kim HY, Chang YJ, Subramanian S, Lee HH, Albacker LA, Matangkasombut P, Savage PB, McKenzie AN, Smith DE, Rottman JB et al. Innate lymphoid cells responding to IL-33 mediate airway hyperreactivity independently of adaptive immunity. J. Allergy Clin. Immunol. 2012; 129: 216–27.e1-6.
67. Aryal S, Diaz-Guzman E, Mannino DM. COPD and gender differences: an update. Transl. Res. 2013; 162: 208–18.
68. Townsend EA, Miller VM, Prakash YS. Sex differences and sex steroids in lung health and disease. Endocr. Rev. 2012; 33: 1–47.
69. Reinhard C, Eder G, Fuchs H, Ziesenis A, Heyder J, Schulz H. Inbred strain variation in lung function. Mamm. Genome 2002; 13: 429–37.
70. Schulz H, Johner C, Eder G, Ziesenis A, Reitmeier P, Heyder J, Balling R. Respiratory mechanics in mice: strain and sex specific differences. Acta Physiol. Scand. 2002; 174: 367–75.
71. Carey MA, Card JW, Bradbury JA, Moorman MP, Haykal-Coates N, Gavett SH, Graves JP, Walker VR, Flake GP, Voltz JW et al. Spontaneous airway hyperresponsiveness in estrogen receptor-alpha-deficient mice. Am. J. Respir. Crit. Care Med. 2007; 175: 126–35.
72. Ben-Zaken Cohen S, Pare PD, Man SF, Sin DD. The growing burden of chronic obstructive pulmonary disease and lung cancer in women: examining sex differences in cigarette smoke metabolism. Am. J. Respir. Crit. Care Med. 2007; 176: 113–20.
73. Chichester CH, Buckpitt AR, Chang A, Plopper CG. Metabolism and cytotoxicity of naphthalene and its metabolites in isolated murine Clara cells. Mol. Pharmacol. 1994; 45: 664–72.
74. Han W, Pentecost BT, Pietropaolo RL, Fasco MJ, Spivack SD. Estrogen receptor alpha increases basal and cigarette smoke extract-induced expression of CYP1A1 and CYP1B1, but not GSTP1, in normal human bronchial epithelial cells. Mol. Carcinog. 2005; 44: 202–11.
75. Jana NR, Sarkar S, Ishizuka M, Yonemoto J, Tohyama C, Sone H. Role of estradiol receptor-alpha in differential expression of 2,3,7, 8-tetrachlorodibenzo-p-dioxin-inducible genes in the RL95-2 and KLE human endometrial cancer cell lines. Arch. Biochem. Biophys. 1999; 368: 31–9.
76. Spink BC, Fasco MJ, Gierthy JF, Spink DC. 12-O-tetradecanoylphorbol-13-acetate upregulates the Ah receptor and differentially alters CYP1B1 and CYP1A1 expression in MCF-7 breast cancer cells. J. Cell. Biochem. 1998; 70: 289–96.
77. Spivack SD, Hurteau GJ, Fasco MJ, Kaminsky LS. Phase I and II carcinogen metabolism gene expression in human lung tissue and tumors. Clin. Cancer Res. 2003; 9: 6002–11.
78. Sin DD, Cohen SB, Day A, Coxson H, Pare PD. Understanding the biological differences in susceptibility to chronic obstructive pulmonary disease between men and women. Proc. Am. Thorac. Soc. 2007; 4: 671–4.
79. Tam A, Churg A, Wright JL, Zhou S, Kirby M, Coxson HO, Lam S, Man SF, Sin DD. Sex differences in airway remodeling in a mouse model of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2016; 193: 825–34.
80. Shih RH, Lee IT, Hsieh HL, Kou YR, Yang CM. Cigarette smoke extract induces HO-1 expression in mouse cerebral vascular endothelial cells: involvement of c-Src/NADPH oxidase/PDGFR/JAK2/STAT3 pathway. J. Cell. Physiol. 2010; 225: 741–50.
81. Nemmar A, Raza H, Subramaniyan D, Yasin J, John A, Ali BH, Kazzam EE. Short-term systemic effects of nose-only cigarette smoke exposure in mice: role of oxidative stress. Cell. Physiol. Biochem. 2013; 31: 15–24.
82. Guo X, Oldham MJ, Kleinman MT, Phalen RF, Kassab GS. Effect of cigarette smoking on nitric oxide, structural, and mechanical properties of mouse arteries. Am. J. Physiol. Heart Circ. Physiol. 2006; 291: H2354–61.
83. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96: 857–68.
84. Hwang JW, Rajendrasozhan S, Yao H, Chung S, Sundar IK, Huyck HL, Pryhuber GS, Kinnula VL, Rahman I. FOXO3 deficiency leads to increased susceptibility to cigarette smoke-induced inflammation, airspace enlargement, and chronic obstructive pulmonary disease. J. Immunol. 2011; 187: 987–98.
85. Nakamaru Y, Vuppusetty C, Wada H, Milne JC, Ito M, Rossios C, Elliot M, Hogg J, Kharitonov S, Goto H et al. A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9. FASEB J. 2009; 23: 2810–9.
86. Yao H, Chung S, Hwang JW, Rajendrasozhan S, Sundar IK, Dean DA, McBurney MW, Guarente L, Gu W, Ronty M et al. SIRT1 protects against emphysema via FOXO3-mediated reduction of premature senescence in mice. J. Clin. Invest. 2012; 122: 2032–45.
87. Knobloch J, Wahl C, Feldmann M, Jungck D, Strauch J, Stoelben E, Koch A. Resveratrol attenuates the release of inflammatory cytokines from human bronchial smooth muscle cells exposed to lipoteichoic acid in chronic obstructive pulmonary disease. Basic Clin. Pharmacol. Toxicol. 2014; 114: 202–9.
88. Liu H, Ren J, Chen H, Huang Y, Li H, Zhang Z, Wang J. Resveratrol protects against cigarette smoke-induced oxidative damage and pulmonary inflammation. J. Biochem. Mol. Toxicol. 2014; 28: 465–71.
89. Sin DD, Hollander Z, DeMarco ML, McManus BM, Ng RT. Biomarker development for chronic obstructive pulmonary disease. From discovery to clinical implementation. Am. J. Respir. Crit. Care Med. 2015; 192: 1162–70.
90. Zhang S, Xu N, Nie J, Dong L, Li J, Tong J. Proteomic alteration in lung tissue of rats exposed to cigarette smoke. Toxicol. Lett. 2008; 178: 191–6.
91. Barnes PJ. New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat. Rev. Drug Discov. 2013; 12: 543–59.
92. Churg A, Wang RD, Tai H, Wang X, Xie C, Wright JL. Tumor necrosis factor-alpha drives 70% of cigarette smoke-induced emphysema in the mouse. Am. J. Respir. Crit. Care Med. 2004; 170: 492–8.
93. D'Hulst AI, Bracke KR, Maes T, De Bleecker JL, Pauwels RA, Joos GF, Brusselle GG. Role of tumour necrosis factor-alpha receptor p75 in cigarette smoke-induced pulmonary inflammation and emphysema. Eur. Respir. J. 2006; 28: 102–12.
94. Medicherla S, Fitzgerald MF, Spicer D, Woodman P, Ma JY, Kapoun AM, Chakravarty S, Dugar S, Protter AA, Higgins LS. p38alpha-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammation. J. Pharmacol. Exp. Ther. 2008; 324: 921–9.
95. Meja KK, Seldon PM, Nasuhara Y, Ito K, Barnes PJ, Lindsay MA, Giembycz MA. p38 MAP kinase and MKK-1 co-operate in the generation of GM-CSF from LPS-stimulated human monocytes by an NF-kappa B-independent mechanism. Br. J. Pharmacol. 2000; 131: 1143–53.
96. Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat. Rev. Drug Discov. 2003; 2: 717–26.
97. Underwood DC, Osborn RR, Bochnowicz S, Webb EF, Rieman DJ, Lee JC, Romanic AM, Adams JL, Hay DW, Griswold DE. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am. J. Physiol. Lung Cell. Mol. Physiol. 2000; 279: L895–902.
98. Duan W, Aguinaldo Datiles AM, Leung BP, Vlahos CJ, Wong WS. An anti-inflammatory role for a phosphoinositide 3-kinase inhibitor LY294002 in a mouse asthma model. Int. Immunopharmacol. 2005; 5: 495–502.
99. Thomas MJ, Smith A, Head DH, Milne L, Nicholls A, Pearce W, Vanhaesebroeck B, Wymann MP, Hirsch E, Trifilieff A et al. Airway inflammation: chemokine-induced neutrophilia and the class I phosphoinositide 3-kinases. Eur. J. Immunol. 2005; 35: 1283–91.
100. Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J. Exp. Med. 2004; 200: 689–95.
101. Owen CA. Roles for proteinases in the pathogenesis of chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2008; 3: 253–68.
102. Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, She D, Kell C, May RD, Geba GP et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur. Respir. J. 2013; 41: 330–8.
103. Mahler DA, Huang S, Tabrizi M, Bell GM. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest 2004; 126: 926–34.
104. Buhl R, Maltais F, Abrahams R, Bjermer L, Derom E, Ferguson G, Fležar M, Hébert J, McGarvey L, Pizzichini E. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur. Respir. J. 2015; 45: 969–79.
105. Donovan C, Bailey SR, Tran J, Haitsma G, Ibrahim ZA, Foster SR, Tang MLK, Royce SG, Bourke JE. Rosiglitazone elicits in vitro relaxation in airways and precision cut lung slices from a mouse model of chronic allergic airways disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 2015; 309: L1219–28.
106. Donovan C, Royce S, Vlahos R, Bourke J. Lipopolysaccharide does not alter small airway reactivity in mouse lung slices. PLoS One 2015; 10: e0122069.